


Infant feeding in the ARV era

**Gerhard Theron
Department of Obstetrics and
Gynaecology
Faculty of Health Sciences and
Tygerberg Hospital**



Global HIV infections: 2007



33 million in world



2011 - 34.2 million



8 million on HAART

22 million in SSA

2011 - 23.5 million



2011

5.7 million in SA

1.7 million on HAART

**12 countries account for
75% of world's HIV-positive pregnant women**

**South Africa has less than 1% of world's population
but 17% of HIV infections**

THE NEW AGE
01 - 02 - 2012

HIV-Aids ‘doubles SA death rate’

THE mortality rate in South Africa has more than doubled since 1985 and birth rates have decreased, the SA Institute for Race Relations (SAIRR) said yesterday.

“In 1985, there were 1 060 000 births and 259 000 deaths in South Africa,” according to the SAIRR’s latest SA Survey.

“In 2011 there were about the same number of births as in 1985, yet more than double the number of deaths (599 000).”

**Deaths due to AIDS
2009 ~ 310,000**

SOUTH AFRICA SURVEY 2010/2011



Demographics • The Economy • Employment & Incomes
Business & Labour • Education • Health & Welfare
Living Conditions & Communications • Crime & Security
Politics & Government



South African Institute
of Race Relations



Unit for Risk Analysis

Projected impact of HIV/AIDS on the size of the South African population^a, 2000-40


<i>Year</i>	<i>Without AIDS</i>	<i>With AIDS</i>	<i>Difference</i>
	<i>Millions</i>		
2000	46.2	45.6	0.6
2005	50.6	48.6	2.0
2010	55.0	50.6	4.4
2015	59.4	51.9	7.5
2020	63.7	52.8	10.9
2025	67.6	53.4	14.2
2030	71.3	53.7	17.6
2035	74.6	53.7	20.9
2040	77.5	53.4	24.1

Source: IFR, *Key demographic trends for South Africa to 2040*, Vol. 15 No. 2, June 2010, Figure 2, Page 2;
Projections of the South African Population, 1985-2040, March 2011, Table A1, p25

a. Numbers are in millions.

Note: For more information on HIV and AIDS, see the Health and Welfare chapter in this Survey.

Projected impact of HIV/AIDS on the size of the South African population, 2000–40



Global PMTCT need

90% ~ 20 countries

High prevalence countries

- **Sub-Saharan Africa + India**
- **Rapid scale up**
 - ❖ **effective interventions**
- **National programmes**

HIV+ pregnant women ARV coverage

Countries	2004 (%)	2007 (%)	2008 (%)
Low to middle income	10	35	45
Eastern + Southern Africa	9	46	58

2010





Figure 5: HIV prevalence distribution by province, South Africa, 2010

Prevalence by age group

Age group	2005	2006	2007	2008	2009	2010
<20	15.9	13.7	13.1	14.0	13.7	14.0
20 - 24	30.6	28.0	28.0	26.9	26.6	26.7
25 – 29	39.5	38.7	37.5	37.9	37.1	37.3
30 - 34	36.4	37.0	39.4	40.4	41.5	42.6
35 - 39	28.0	29.3	33.0	32.4	35.4	38.4
40 - 44	21.3	22.2	23.3	25.6	30.9	
45+	19.8	15.5	20.6	17.6	23.9	28.2

Antenatal HIV Prevalence South Africa (%)



Our Challenge

- An effective PMTCT programme will reduce the number of perinatal acquired HIV infections
 - ➔ This is a goal within reach of the SA Public Health Sector
- Key Priority Area 1: SANAC HIV/AIDS & STI National Strategic Plan for 2007 - 2011
 - ➔ Scale up coverage + improve quality of PMTCT to reduce MTCT to <5%

The Health Specific MDGs

- 4. Reduce child mortality**
 - **Reduce children under 5 mortality by 2/3**
- 5. Improve maternal health**
 - **Reduce maternal mortality by 3/4**
 - **Universal access to reproductive health**
- 6. Combat HIV/AIDS, malaria and other diseases (TB)**

A Comparison of Primary Obstetric Causes of Death between 1999-2007

Primary Obstetric Cause	1999-2001		2002-2004		2005-2007	
	N	%	N	%	N	%
Direct						
Hypertension	1462	59.8	1767	53.6	1819	45.9
Postpartum haemorrhage	507	20.7	628	19.1	622	15.7
Antepartum haemorrhage	240	9.8	313	9.5	383	9.7
Ectopic pregnancy	100	4.1	129	3.9	108	2.7
Abortion	27	1.1	47	1.4	55	1.4
Pregnancy Related Sepsis	120	4.9	114	3.5	136	3.4
Anaesthetic related	210	8.6	274	8.3	223	5.6
Embolism	76	3.1	91	2.8	107	2.7
Acute collapse	48	2	64	1.9	57	1.4
	134	5.5	107	3.2	128	3.2
Indirect	939	38.4	1430	43.4	1966	49.7
Non pregnancy related Infections	768	31.4	1246	37.8	1729	43.7
AIDS	416	17	662	20.1	915	23.1
Pre-existing Maternal Disease	171	7	184	5.6	237	6.0
Unknown	44	1.8	99	3	174	4.4
Total	2445	100	3296	100	3959	100
Coincidental	45		110		118	

National PMTCT - 2010

Antenatally

- 1st visit - PIT & C + HIV rapid testing
 - HIV+ posttest counseling
 - CD4 count
- 2nd visit ONE week later
 - infant feeding options
- CD4 count
 - > 350/ μ l + stage 1 or 2
 - AZT 300mg 2/day 14 wks \Rightarrow labour
 - \leq 350 / μ l \pm 30% or stage 3 & 4
 - HAART (ART clinics)

National PMTCT - 2010

Intrapartum - knowledge of status

sdNVP 200mg + AZT 300mg 3hrly

Neonatally

>2kg NVP 0.6 ml at birth + daily \Rightarrow 6 wks

- **Formula / exclusive breast feeding**
- **BF continue NVP \Rightarrow 1 wk after weaning
for dual therapy group**
- **Follow-up: 6wks co-trimoxazole**
- **PCR at 6 weeks**

PMTCT ~ Questions

- HAART vs dual therapy CD4 >350?
- Neonatal PEP ~ mothers no ARVs?
- NVP resistance?
- Protease inhibitors and preterm labour?
- BF and ARV prophylaxis?
- Present transmission rates?

Option B+

WHO Programmatic update – April 2012

- **HAART regardless CD4 count for life**
- **Single pill fixed dose – TDF/3TC/EFV**
- **USD 180/yr**

Motivation – E Schouten, Lancet, July 2011

- **# CD4 count often not possible**
- **Death rate HIV+ CD4 >350 ~ <24 mths**
- **6 fold↑ ~ Zimbabwe vs HIV neg**
{AIDS 2010 JW Hargrove}
- **2 - 3 yrs ~ research results not ethical**

Concerns - Option B +


EFV exposure – 1st trimester

- Ford et al AIDS 2011
 - ❖ Efavirenz vs non-EFV based regimens
 - ❖ RR 0.85 (95% CI 0.61 – 1.20)
- Knapp et al Pediatr Infect Dis J 2012
 - ❖ Prospective studies (P1025)
 - ❖ 47 1st trim expos 6 (12.8%) cong abn

TNF-containing HAART

- Siberry et al AIDS 2012
 - ❖ ↓ length of age + head circum at 1yr

Timing of HIV Transmission – pre ARV era



4% Transmission of HIV for every 6 months of breast-feeding

ARV's + PMTCT

Transmission remains significantly higher

- **↑ viral load**
- **Vaginal delivery vs C/S prior to onset of labour**
- **Preterm delivery**

Protease inhibitors + preterm labour

- Tuomala et al* ~ 7 PACTG studies
- N = 2173

HAART	Without PI n = 396 (%)	With PI n = 137 (%)	P-value
LBW <2500g	41 (11)	27 (20)	0.009
<32 weeks	10 (3)	6 (4)	0.17
CD4 <200	28%	43%	

- HAART + PI ~ more advanced disease?
- European Collaborative Group # NS

*NEJM 2002

CID 2005

HAART + preterm labour

More recent studies (BJOG Oct 2010)

- 1.4 – 3.4 increased risk
- Dual therapy vs HAART
(HAART containing PIs ↑ risk)
- Lack of control of cofounders ~ comparisons difficult
- Possible mechanism
 - ❖ Reversal TH1 + TH2 cytokine switch
 - ❖ TH2 cytokines IL10 + IL4 maintain fetal allograft

Infants exposed to maternal sdNVP

Lockman et al*

- Maternal sd NVP exposed infants

- 1° end point ~ at 24 weeks

- Virologic failure or death

Trial 1 ~ n 241	End point (%)	HR (95% CI)
PI# + Truvada	10 (8)	3.6 (1.7 – 7.5)
NVP + Truvada	32 (26)	p 0.001

*NEJM Oct 2010

#ritonavir-boosted lopinavir

24 months post NVP exp (n 65) HR 1.3 (0.3 – 6.1)

NVP naïve infants

Lockman et al*

- Not exposed to maternal sd NVP
 - 1° end point ~ at 24 weeks
 - Virologic failure or death


Trial 2 ~ n 452	End point (%)	HR (95% CI)
PI# + Truvada	12.3	3.6 (1.7 – 7.5) p 0.001
NVP + Truvada	28.6	

*NIAID Web Bulletin Nov 2010


#ritonavir-boosted lopinavir

Policy on infant + young child feeding

- **2010 WHO Guidelines**
 - ~ promotes breast feeding
- **August 2011 – adopted by SA**




Mortality through Age 7 Months is Higher in Formula Fed than Breast Fed Infants



Main causes infant death: diarrheal disease + pneumonia
Death of HIV+ by 18 months p=0.6 Mashi study JAMA 2006


KwaZulu Natal Clinics

7 rural, 1 semi urban, 1 urban ~ Lancet 2007



p=0.051 HR 2.1 (1.0 – 4.3)

BAN* Study: Probability of HIV+ or Death by 28 week visit in infants uninfected at birth



*NEJM 2010

Cost analysis

WHO analysis ~ southern Africa

- Cost per 10,000 HIV + mothers
- CD4 ≤ 350 HAART
- CD4 > 350 Dual therapy

Breastfeeding	US\$ 522,542
Formula milk for 6 mths	US\$ 2,063,100

Prevention of postnatal transmission

HPTN 046

Safety and efficacy

Once day NVP extended ⇒ 6 months

- SA, Tanzania, Uganda + Zimbabwe
- HIV neg 6 wks ⇒ HIV + at 6 months
- 1527 infants randomised
- Lancet Dec 2011

HPTN 046 - results

6 months	Extended NVP	Placebo	Rel RR	P value
All patients*	8/700 1.1%	18/699 2.4%	54% ↓	0.049
On HAART ~ CD4	1/210 0.5%	0/203 --	--	--
No HAART ~ CD4*	7/490 1.3%	18/492 3.4%	62% ↑	0.027
≥CD4 no HAART#	3/418 0.7%	13/434 2.8%	75% ↓	0.014
<CD4 no HAART	4/71 4.8%	5/54 8.1%	41% ↓	0.44

*Not sustained through to 9 and 12 months

#Sustained through to 9 but not to 12 months

HPTN 046 - results




Figure 2: Kaplan-Meier analysis of breastfeeding duration, by study group

HPTN 046 – Adverse events

Adverse events	Overall	Ext NVP	Placebo	P value
Possibly related*	169 (11%)	87 (12%)	82 (11%)	0.66
Neutropenia	249 (19%)	161 (21%)	133 (18%)	0.07
↑ ALT	6 (<1%)	3 (<1%)	3 (<1%)	1.00
Anaemia	354 (23%)	188 (25%)	166 (22%)	0.18

* Rash

Suppression of lactation

ZEB study (AIDS 2006)

- Viral load – breast milk (median)
 - pre-weaning 353 copies/ml
 - post-weaning 15822 copies/ml
- Breast engorgement
 - duct endothelium damage
 - ↑ viral load in milk

Suppression of lactation

- **Bromocriptine (Parludel) 2.5 mg tab**
 - 2.5mg 2/day 7 days - R41.16
- **Carbecoline (Dostinex) 0.5 mg tab - R70.50**
 - 1 mg as single dose postpartum
 - 0.25 mg 2/day 2days
- **Problem**
 - expensive
 - level 2 and 3 hospitals only
- **Contra-indicated with hypertension**


Practical option

- Non-pharmacologic method
 - advice
 - ❖ don't resume!
 - rapid weaning
 - milk out until comfortable
 - moderate compression
- Piridoxine ✗


Preterm infants - TBH

- Large neonatal service
- High preterm delivery rate
 - ❖ Obstetric beds 107
 - ❖ Neonatal high care beds 140
- Mother's milk always used
 - ❖ Pasteurised if HIV+
 - ❖ Kangaroo care
- Mother's choice at discharge respected

Transmission Rate: W Cape



BED OCCUPANCY RATE (BOR)



World AIDS Day 2009:
“It is the time to act decisively,
and to act together.”

Thank you
Enkosi kakhulu
Baie dankie!



Evaluation of Effectiveness of the National PMTCT Programme Six Weeks Postpartum South Africa

Ameena Goga, MRC/HSRU

Thu-Ha Dinh, US CDC/GAP

Debra Jackson, UWC, MRC/HSRU



Background - Sample Size

Province	Desired SS	Actual SS (prov%)
Eastern Cape	1400	753 (54%)
Free State	1300	1123 (86%)
Gauteng	1800	1712 (95%)
KwaZulu-Natal	1400	1205 (86%)
Limpopo	1400	982 (70%)
Mpumalanga	1600	1252 (78%)
Northern Cape	700	390 (56%)
North West	1200	1156 (96%)
Western Cape	1400	1342 (96%)
SA	12 200	9915 (81%)

Sample size calculated to obtain valid national and provincial level MTCT rates

Weighted MTCT Rate at 4-8 weeks

Province	Infant HIV exposure (%)	MTCT (%) 95% CI
Eastern Cape	30.0 (26.3 - 33.7)	3.5 (1.2 - 5.8)
Free State	31.1 (28.9 - 33.3)	5.7 (3.5 - 7.9)
Gauteng	30.2 (27.7 - 32.8)	2.3 (1.3 - 3.3)
KwaZulu-Natal	43.9 (39.7 - 48.0)	2.8 (1.7 - 4.0)
Limpopo	22.6 (20.4 - 24.8)	3.4 (1.0 - 5.8)
Mpumalanga	36.2 (33.6 - 38.9)	6.2 (4.5 - 7.9)
Northern Cape	15.6 (13.0 - 18.3)	1.9 (0.1 - 4.5)
Northwest	30.9 (28.6 - 33.1)	4.6 (3.0 - 6.1)
Western Cape	20.8 (16.8 - 24.9)	3.3 (1.3 - 5.2)
SA	31.4 (30.1 - 32.6)	3.5 (2.9 - 4.1)

MTCT Rate at 4-8 weeks ~ 2010 +2011

Province	2010 (%)	2011 (%)
Eastern Cape	3.5	3.8
Free State	5.7	3.8
Gauteng	2.3	2.1
KwaZulu-Natal	2.8	2.1
Limpopo	3.4	3.1
Mpumalanga	6.2	3.3
Northern Cape	1.9	6.1
Northwest	4.6	2.6
Western Cape	3.3	2.0
SA	3.5	2.7